Stock investor since 1988; evolved to primarily a swing trader/ momentum-data trader since the economic bust in 2008 keeping long positions with my favorites. I'm also invested in real estate.
Focused on the precious metals, energy, life sciences and other metals sectors. Streetwise Reports features the leading investment coverage of gold, oil, uranium, biotech, pharma, rare earths, alternative energy, silver, platinum, medtech & potash.
Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon® vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These vacc
... moreines, in combination with Inovio’s proprietary electroporation delivery devices, have been shown in humans to be safe and generate best-in-class immune responses. Inovio’s clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative.less
Safe Harbor Statement
This contains certain forward-looking statements relating to our business, including our plans to...
Sr. Director of Corporate Communications
1787 Sentry Parkway West
Building 18, Suite 400
Blue Bell, PA, 19422
United States of America